不同剂量依巴斯汀联合复方甘草酸苷递减疗法治疗慢性荨麻疹的临床研究  

Clinical study on the treatment of chronic urticaria with different doses of ebastine combined with compound glycyrrhizin decremental therapy

作　　者：陈婷 张玉兰 杨荣明 Chen Ting;Zhang Yu-lan;Yang Rong-ming(Department of Dermatology,Shangyou People's Hospital,Ganzhou 341200,Jiangxi,China)

机构地区：[1]上犹县人民医院皮肤科,江西赣州341200

出　　处：《四川生理科学杂志》2024年第7期1477-1479,共3页

基　　金：赣州市指导性科技计划项目(编号:GZ2023ZSF601)。

摘　　要：目的:研究不同剂量依巴斯汀联合复方甘草酸苷递减疗法治疗慢性荨麻疹的临床应用效果。方法:选取2022年1月至2023年9月我院就诊的44例慢性荨麻疹患者为研究对象。按照不同治疗方案分为对照组和观察组,各22例。对照组采用10 mg依巴斯汀片,观察组采用20 mg依巴斯汀,两组均联合复方甘草酸苷递减疗法治疗。比较两组治疗前后临床症状积分、血液学指标[血清白介素-17(Interleukin-17,IL-17)、白介素-25(Interleukin-25,IL-25)、白介素-33(Interleukin,33,IL-33)]、T淋巴细胞计数[辅助性T细胞(Helper T cell,CD4^(+))、细胞毒性T细胞(Cytotoxic T cell,CD8^(+))]水平、临床疗效及用药不良反应发生率。结果:治疗后,观察组临床症状积分总有效率均高于对照组(P<0.05);观察组总有效率均高于对照组(P<0.05);治疗后,观察组IL-17、IL-25、IL-33及CD8^(+)均低于对照组,CD4^(+)高于对照组(P<0.05);两组不良反应发生率无显著差异。结论:20 mg依巴斯汀联合复方甘草酸苷递减疗法可以更有效缓解慢性荨麻疹患者临床症状,降低血清IL-17、IL-25、IL-33水平,改善机体免疫功能,且较为安全。Objective:To study the clinical effects of different doses of ebastine combined with compound glycyrrhizin decremental therapy in the treatment of chronic urticaria.Methods:A total of 44 patients with chronic urticaria treated in our hospital from January 2022 to September 2023 were selected as the study subjects.They were divided into the control group and the observation group according to different treatment plans,with 22 cases in each group.The control group was treated with 10 mg of ebastine tablets,and the observation group was treated with 20 mg of ebastine.Both groups were given compound glycyrrhizin decremental therapy.Clinical symptom scores,hematological indicators[interleukin-17(IL-17),interleukin-25(IL-25)and interleukin-33(IL-33)],T lymphocyte count[helper T cell(CD4^(+))and cytotoxic T cell(CD8^(+))],clinical effects,and the incidence of adverse drug reactions were compared between the two groups.Results:After treatment,clinical symptom scores of the observation group were lower than those of the control group(P<0.05),and total effective rate was higher than that of the control group(P<0.05).After treatment,the levels of IL-17,IL-25,IL-33 and CD8^(+)in the observation group were lower than those in the control group,and the level of CD4^(+)was higher than that in the control group(P<0.05).The incidence rates of adverse reactions in the two groups were similar.Conclusion:20 mg of ebastine combined with compound glycyrrhizin decremental therapy can alleviate clinical symptoms in patients with chronic urticaria more effectively,reduce serum IL-17,IL-25 and IL-33 levels,and improve immune function,with quite high safety.

关 键 词：依巴斯汀 不同剂量 复方甘草酸苷 递减疗法 慢性荨麻疹 临床研究 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]